{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T04:39:16Z","timestamp":1792471156657,"version":"4.5.0"},"reference-count":52,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd016347","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T12:23:37Z","timestamp":1775046217000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Lenacapavir as pre-exposure prophylaxis for HIV prevention"],"prefix":"10.1002","volume":"2026","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9822-6347","authenticated-orcid":false,"given":"Sumayyah","family":"Ebrahim","sequence":"additional","affiliation":[{"name":"Health Systems Research Unit; South African Medical Research Council; Cape Town South Africa"},{"name":"South African GRADE Network; Cape Town South Africa"},{"name":"Discipline of General Surgery, Nelson R Mandela School of Medicine; University of KwaZulu-Natal; Durban South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2533-9540","authenticated-orcid":false,"given":"Natasha","family":"Gloeck","sequence":"additional","affiliation":[{"name":"Health Systems Research Unit; South African Medical Research Council; Cape Town South Africa"},{"name":"South African GRADE Network; Cape Town South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2050-8915","authenticated-orcid":false,"given":"Zahiera","family":"Adam","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative; Pretoria South Africa"},{"name":"Affordable Medicines Directorate; National Department of Health; Pretoria South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5975-3566","authenticated-orcid":false,"given":"Gayle","family":"Tatz","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology; University of Cape Town; Cape Town South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4115-894X","authenticated-orcid":false,"given":"Jeremy","family":"Nel","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine; Faculty of Health Sciences, University of the Witwatersrand; Johannesburg South Africa"},{"name":"Infectious Diseases and Oncology Research Institute; University of the Witwatersrand; Johannesburg South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1312-3523","authenticated-orcid":false,"given":"Phumla Z","family":"Sinxadi","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology; University of Cape Town; Cape Town South Africa"},{"name":"SAMRC\/UCT Platform for Pharmacogenomics Research and Translation; South African Medical Research Council; Cape Town South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8180-6791","authenticated-orcid":false,"given":"Halima","family":"Dawood","sequence":"additional","affiliation":[{"name":"Infectious Diseases unit; Greys hospital; Pietermaritzburg South Africa"},{"name":"Caprisa; University of Kwazulu Natal; Durban South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7115-9535","authenticated-orcid":false,"given":"Tamara","family":"Kredo","sequence":"additional","affiliation":[{"name":"Health Systems Research Unit; South African Medical Research Council; Cape Town South Africa"},{"name":"South African GRADE Network; Cape Town South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1892-4207","authenticated-orcid":false,"given":"Karen","family":"Cohen","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology; University of Cape Town; Cape Town South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"10.1002\/14651858.CD016347-BIB0001|cit1","unstructured":"AIDS Info: Global data on HIV epidemiology and response https:\/\/aidsinfo.unaids.org"},{"key":"10.1002\/14651858.CD016347-BIB0002|cit2","unstructured":"Centers for Disease Control and Prevention Diagnoses, deaths, and prevalence of HIV in the United States and 6 territories and freely associated states, 2022 http:\/\/www.cdc.gov\/hiv-data\/nhss\/hiv-diagnoses-deaths-prevalence.html"},{"key":"10.1002\/14651858.CD016347-BIB0003|cit3","unstructured":"Centers for Disease Control and Prevention Estimated HIV incidence and prevalence in the United States, 2018\u20132022 https:\/\/www.cdc.gov\/ hiv-data\/nhss\/estimated-hiv-incidence-and-prevalence.html"},{"key":"10.1002\/14651858.CD016347-BIB0004|cit4","unstructured":"Joint United Nations Programme on HIV\/AIDS The urgency of now: AIDS at a crossroads. [online] https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/2024-unaids-global-aids-update_en.pdf"},{"issue":"4","key":"10.1002\/14651858.CD016347-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"495","DOI":"10.53854\/liim-3104-8","article-title":"Pharmacological outlook of lenacapavir: a novel first-in-class-acting HIV-1 capsid inhibitor","volume":"31","author":"Di Perri","year":"2023","journal-title":"Infezioni in Medicina"},{"key":"10.1002\/14651858.CD016347-BIB0006|cit6","unstructured":"Sax PE Lenacapavir PrEP trial brings down the house at the International AIDS Conference. HIV and ID Observations https:\/\/blogs.jwatch.org\/hiv-id-observations\/index.php\/Lenacapavir-prep-trial-brings-down-the-house-at-the-international-aids-conference\/2024\/07\/25\/"},{"key":"10.1002\/14651858.CD016347-BIB0007|cit7","unstructured":"World Health Organization FDA approval of injectable lenacapavir marks progress for HIV prevention. [online] https:\/\/www.who.int\/news\/item\/19-06-2025-fda-approval-of-injectable-Lenacapavir-marks-progress-for-hiv-prevention"},{"key":"10.1002\/14651858.CD016347-BIB0008|cit8","unstructured":"Injectable lenacapavir for PrEP https:\/\/www.prepwatch.org\/products\/lenacapavir-for-prep\/"},{"key":"10.1002\/14651858.CD016347-BIB0009|cit9","doi-asserted-by":"publisher","DOI":"10.2471\/B09477","volume-title":"Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis (PrEP)","author":"Fonner","year":"2025"},{"key":"10.1002\/14651858.CD016347-BIB0010|cit10","unstructured":"Higgins JP Lasserson T Thomas J Flemyng E Churchill R Methodological Expectations of Cochrane Intervention Reviews. Cochrane: London, Version August 2023 Available from https:\/\/community.cochrane.org\/mecir-manual"},{"key":"10.1002\/14651858.CD016347-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD016347-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jclinepi.2020.10.007","article-title":"Cochrane Rapid Reviews Methods Group offers evidence-informed guidance to conduct rapid reviews","volume":"130","author":"Garritty","year":"2021","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD016347-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"e076335","DOI":"10.1136\/bmj-2023-076335","article-title":"Updated recommendations for the Cochrane rapid review methods guidance for rapid reviews of effectiveness","volume":"384","author":"Garritty","year":"2024","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD016347-BIB0014|cit14","unstructured":"Sch\u00fcnemann H Bro\u017cek J Guyatt G Oxman A Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013 Available at https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html"},{"key":"10.1002\/14651858.CD016347-BIB0015|cit15","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence (chapter last updated August 2023). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.cochrane.org\/handbook"},{"issue":"13","key":"10.1002\/14651858.CD016347-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1056\/NEJMoa2407001","article-title":"Twice-yearly lenacapavir or daily F\/TAF for HIV prevention in cisgender women","volume":"391","author":"Bekker","year":"2024","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD016347-BIB0017|cit17","unstructured":"Pre-exposure prophylaxis study of lenacapavir and emtricitabine\/\u200btenofovir alafenamide in adolescent girls and young women at risk of HIV infection (PURPOSE 1) https:\/\/clinicaltrials.gov\/study\/NCT04994509"},{"key":"10.1002\/14651858.CD016347-BIB0018|cit18","unstructured":"Pre-exposure prophylaxis study of lenacapavir and emtricitabine\/tenofovir alafenamide in adolescent girls and young women at risk of HIV infection https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=EUCTR2023-001024-42-Outside-EU%2FEEA"},{"issue":"13","key":"10.1002\/14651858.CD016347-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1056\/NEJMoa2411858","article-title":"Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons","volume":"392","author":"Kelley","year":"2025","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD016347-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"e0267780","DOI":"10.1371\/journal.pone.0267780","article-title":"Proactive strategies to optimize engagement of Black, Hispanic\/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP)","volume":"17","author":"Cespedes","year":"2022","journal-title":"PLOS One"},{"key":"10.1002\/14651858.CD016347-BIB0021|cit21","unstructured":"Pre-exposure prophylaxis study of lenacapavir in cisgender men, transgender women, transgender men, and gender nonbinary people at risk for HIV infection https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2023-001025-23\/3rd\/"},{"key":"10.1002\/14651858.CD016347-BIB0022|cit22","unstructured":"Study of lenacapavir for HIV pre-exposure prophylaxis in people who are at risk for HIV infection (PURPOSE 2) https:\/\/clinicaltrials.gov\/study\/NCT04925752"},{"key":"10.1002\/14651858.CD016347-BIB0023|cit23","unstructured":"Peryer G Golder S Junqueira D Vohra S Loke YK Chapter 19: Adverse effects (chapter last updated October 2019). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016347-BIB0024|cit24","unstructured":"Lefebvre C Glanville J Briscoe S Featherstone R Littlewood A Chapter 4: Searching for and selecting studies (chapter last updated September 2024). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016347-BIB0025|cit25","unstructured":"Lefebvre C Glanville J Briscoe S Featherstone R Littlewood A Technical Supplement to Chapter 4: Searching for and selecting studies (last updated September 2024). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from https:\/\/www.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016347-BIB0026|cit26","unstructured":"Covidence Veritas Health Innovation 2025"},{"key":"10.1002\/14651858.CD016347-BIB0027|cit27","unstructured":"Higgins JP Savovi\u0107 J Page MJ Elbers RG Sterne JA Chapter 8: Assessing risk of bias in a randomized trial (chapter last updated October 2019). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016347-BIB0028|cit28","unstructured":"Boutron I Page MJ Higgins JP Altman DG Lundh A Hr\u00f3bjartsson A Chapter 7: Considering bias and conflicts of interest among the included studies (chapter last updated August 2022). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016347-BIB0029|cit29","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2025"},{"key":"10.1002\/14651858.CD016347-BIB0030|cit30","unstructured":"Higgins JP Li T Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect (chapter last updated August 2023). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016347-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"l6890","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"issue":"414","key":"10.1002\/14651858.CD016347-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD016347-BIB0033|cit33","unstructured":"Deeks JJ Higgins JP Altman DG McKenzie JE Veroniki AA Chapter 10: Analysing data and undertaking meta-analyses (chapter last updated November 2024). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016347-BIB0034|cit34","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2025"},{"key":"10.1002\/14651858.CD016347-BIB0035|cit35","unstructured":"Equity in the HIV response: Assessing progress and charting a way forward https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/equity-in-the-hiv-response_en.pdf"},{"key":"10.1002\/14651858.CD016347-BIB0036|cit36","unstructured":"HIV and stigma and discrimination: Human rights fact sheet series https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/07-hiv-human-rights-factsheet-stigma-discrmination_en.pdf"},{"key":"10.1002\/14651858.CD016347-BIB0037|cit37","unstructured":"Study of lenacapavir and emtricitabine\/\u200btenofovir disoproxil fumarate (F\/\u200bTDF) in prevention of HIV in cisgender women in the United States (HPTN 102) (PURPOSE 3) 2023. Available From: https:\/\/clinicaltrials.gov\/study\/NCT06101329?tab=table"},{"key":"10.1002\/14651858.CD016347-BIB0038|cit38","unstructured":"Study of lenacapavir and emtricitabine\/tenofovir disoproxil fumarate (F\/TDF) for prevention of HIV in people who inject drugs (HPTN 103) (PURPOSE 4) 2023. Available from https:\/\/www.clinicaltrials.gov\/study\/NCT06101342?term=NCT06101342&rank=1"},{"key":"10.1002\/14651858.CD016347-BIB0039|cit39","unstructured":"Study of lenacapavir taken twice a year for HIV pre-exposure prophylaxis (PrEP) (PURPOSE 5) 2024. Available from https:\/\/clinicaltrials.gov\/study\/NCT06513312"},{"key":"10.1002\/14651858.CD016347-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD016347-BIB0041|cit41","unstructured":"Higgins JP Eldridge S Li T Chapter 23: Including variants on randomized trials (chapter last updated October 2019). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.cochrane.org\/handbook"},{"issue":"1","key":"10.1002\/14651858.CD016347-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jclinepi.2013.08.005","article-title":"Applying an equity lens to interventions: using PROGRESS ensures consideration of socially stratifying factors to illuminate inequities in health","volume":"67","author":"O'Neill","year":"2014","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD016347-BIB0043|cit43","unstructured":"World Health Organization Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis (PrEP) https:\/\/www.who.int\/publications\/i\/item\/9789240111608"},{"issue":"1","key":"10.1002\/14651858.CD016347-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"a1497","DOI":"10.4102\/sajhivmed.v24i1.1497","article-title":"Promises and potential pitfalls of long-acting injectable pre-exposure prophylaxis","volume":"24","author":"Pike","year":"2023","journal-title":"Southern African Journal of HIV Medicine"},{"issue":"1","key":"10.1002\/14651858.CD016347-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"5760","DOI":"10.1038\/s41467-025-60752-y","article-title":"Potential impact and cost-effectiveness of long-acting injectable lenacapavir plus cabotegravir as HIV treatment in Africa","volume":"16","author":"Phillips","year":"2025","journal-title":"Nature Communications"},{"issue":"2","key":"10.1002\/14651858.CD016347-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"e26427","DOI":"10.1002\/jia2.26427","article-title":"Cost thresholds for anticipated long-acting HIV pre-exposure prophylaxis products in Eastern and Southern Africa: a mathematical modelling study","volume":"28","author":"Kaftan","year":"2025","journal-title":"Journal of the International AIDS Society"},{"issue":"11","key":"10.1002\/14651858.CD016347-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"e765","DOI":"10.1016\/S2352-3018(24)00239-X","article-title":"Health impact, budget impact, and price threshold for cost-effectiveness of lenacapavir for HIV pre-exposure prophylaxis in eastern and southern Africa: a modelling analysis","volume":"11","author":"Wu","year":"2024","journal-title":"Lancet. HIV"},{"key":"10.1002\/14651858.CD016347-BIB0048|cit48","unstructured":"ChatGPT (October GPT-5.1) [Large language model] OpenAI 2025"},{"key":"10.1002\/14651858.CD016347-BIB0049|cit49","unstructured":"Grammarly Superhuman 2025"},{"key":"10.1002\/14651858.CD016347-BIB0050|cit50","unstructured":"Gilead Sciences Sunlenca is a long-acting sc injectable administered only twice a year https:\/\/www.sunlencahcp.com\/dosing-and-administration\/sunlenca-dosing and https:\/\/www.gilead.com\/-\/media\/files\/pdfs\/medicines\/hiv\/sunlenca\/sunlenca_pi.pdf"},{"key":"10.1002\/14651858.CD016347-BIB0051|cit51","unstructured":"European Medicines Agency Apretude [cabotegravir]: Annex 1. 2025 https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/apretude and https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/apretude-epar-product-information_en.pdf"},{"key":"10.1002\/14651858.CD016347-BIB0052|cit52","unstructured":"ViiV Healthcare UK Ltd Apretude 30 mg film-coated tablets: summary of product characteristics https:\/\/www.medicines.org.uk\/emc\/product\/15694\/smpc\/print"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T04:01:40Z","timestamp":1792468900000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD016347"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":52,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd016347","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]}}}